Evaluating Virechana and Hamsapathyadi Kashayam in Hypothyroidism- A Clinical and Computational Analysis

A Clinical and In-Silico Study to Assess the Efficacy of Virechana Followed by Oral Medications and Analysis of Outcomes of Hamsapathyadi Kashayam on THRa And THRß In Hypothyroidism - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/066907

Enrollment

Registered

2024-05-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E039- Hypothyroidism, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between 21 to 60 years of age of either sex. 2. Patients with the symptomatology of hypothyroidism and elevated TSH. 3. Hypothyroid patients with associated Dyslipidemias [13][14]. 4. Patients willing to participate in the trial.

Exclusion criteria

Exclusion criteria: 1. Conditions contraindicated for Snehana and Virechana Procedure. 2. Any other thyroid pathology or any other endocrine disorders like DM, PCOS, Hyperparathyroidism, etc. 3. Pregnant females and breastfeeding mothers. 4. Any other major systemic illnesses like CAD, IHD, Arrhythmias, Vulvar Heart disease, CVA, Abnormal BP, Aortic Aneurysm, etc.

Design outcomes

Primary

Measure	Time frame
Part 1- Improvement in TSH level correction (Assumed value of TSH i.e., 7mIU/L would decline to 5.5mIU/L after the intervention) Part 2- Positive computational outcomes of Hamsapathyadi kashayam’s stimulatory effects on THRa & THRß. Timepoint: To be assessed thrice at 0th, 49th, 98th day	—

Secondary

Measure	Time frame
1. Improvement in clinical features of hypothyroidism. 2. Improvement in lipid profile in Hypothyroidism-mediated dyslipidemias through- HDL lower than 40 mg/dL TC more than 200 mg/dL TG more than 140 mg/dL TC/HDL more than 05 3. Improvement in Apo-B levels hence lowering risk factors for atherosclerotic changes and CVS accidents. 4. Assessment of QOL of hypothyroid patients. Timepoint: Lipid profile- To be assessed thrice at 0th, 49th, 98th day apolipo-B- To be assessed thrice at 0th, 49th, 98th day QOL assessment- To be assessed thrice at 0th, 49th, 98th day	—

Measure

Time frame

1. Improvement in clinical features of hypothyroidism. 2. Improvement in lipid profile in Hypothyroidism-mediated dyslipidemias through- HDL lower than 40 mg/dL TC more than 200 mg/dL TG more than 140 mg/dL TC/HDL more than 05 3. Improvement in Apo-B levels hence lowering risk factors for atherosclerotic changes and CVS accidents. 4. Assessment of QOL of hypothyroid patients. Timepoint: Lipid profile- To be assessed thrice at 0th, 49th, 98th day apolipo-B- To be assessed thrice at 0th, 49th, 98th day QOL assessment- To be assessed thrice at 0th, 49th, 98th day

—

Countries

India

Contacts

Public ContactTanzeem Shaikh

All India Institue of Ayurveda

dr.ananthramsharma@gmail.com9495130595

Outcome results